Does TAFASITAMAB Cause Diffuse large b-cell lymphoma recurrent? 30 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 30 reports of Diffuse large b-cell lymphoma recurrent have been filed in association with TAFASITAMAB (MONJUVI). This represents 2.2% of all adverse event reports for TAFASITAMAB.
30
Reports of Diffuse large b-cell lymphoma recurrent with TAFASITAMAB
2.2%
of all TAFASITAMAB reports
2
Deaths
2
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma recurrent From TAFASITAMAB?
Of the 30 reports, 2 (6.7%) resulted in death, 2 (6.7%) required hospitalization.
Is Diffuse large b-cell lymphoma recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFASITAMAB. However, 30 reports have been filed with the FAERS database.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
What Other Drugs Cause Diffuse large b-cell lymphoma recurrent?
RITUXIMAB (1,359)
CYCLOPHOSPHAMIDE (1,007)
VINCRISTINE (957)
DOXORUBICIN (953)
PREDNISONE (738)
CYTARABINE (406)
DEXAMETHASONE (402)
ETOPOSIDE (375)
CISPLATIN (306)
GEMCITABINE (280)
Which TAFASITAMAB Alternatives Have Lower Diffuse large b-cell lymphoma recurrent Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR